Preclinical In Vitro Drug Contract Research Organization (CRO) for Biotech and Pharma

This listing presents a well-established Contract Research Organization (CRO) specializing in preclinical in vitro drug discovery services. Serving the biotech and pharmaceutical sectors, the company has demonstrated robust growth from 2020 to 2023, with revenue increasing at a 21.8% CAGR and adjusted EBITDA at a 61.8% CAGR. The business benefits from strong customer retention, evidenced by an average of 60.3% annual recurring revenue. Opportunities for further growth include expanding sales and marketing efforts, leveraging corporate partnerships for service expansion, scaling operations to full facility capacity, and entering underserved geographic markets. The company operates in the Northeast United States.